This is an excellent question and one that many patients are asking.

It is important to understand that gene therapy for hearing loss is still in the experimental stage. Current studies are early-phase clinical trials focused on safety and effectiveness, and these treatments are not yet widely available to the general public.

Additionally, the gene therapy that has received recent attention is targeted to a very specific genetic cause of hearing loss—OTOF-related auditory neuropathy. This condition represents a small subset of childhood hearing loss and does not apply to most adults with progressive or long-standing hearing loss.

For a 40-year-old adult who is a candidate for a cochlear implant, delaying evaluation in hopes of future gene therapy is unlikely to be advantageous. Cochlear implants are well-established, FDA-approved, and supported by decades of outcome data in adults. Earlier intervention can help reduce the long-term effects of auditory deprivation and improve communication and quality of life.

Pursuing a cochlear implant evaluation does not obligate you to surgery, but it does provide valuable information to help you make an informed decision.